ALNYLAM PHARMACEUTICALS, INC. (ALNY) FY2026 YTD Q2 P&L / Income Statement

ALNYLAM PHARMACEUTICALS, INC. (ALNY) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

2,458,123,000 US dollars

Cost of goods sold

505,781,000 US dollars

Gross profit (calculated)

1,952,342,000 US dollars

Operating expenses (calculated)

1,452,265,000 US dollars

Income (loss) from operations

500,077,000 US dollars

Total other expense, net

negative 100,618,000 US dollars

Income (loss) before income taxes

399,459,000 US dollars

Provision for income taxes

28,974,000 US dollars

Net income (loss)

370,485,000 US dollars

Net revenues from collaborations

129,240,000 US dollars

Royalty revenue

120,647,000 US dollars

Amvuttra - Rest of World

157,737,000 US dollars

Amvuttra - UNITED STATES

1,511,633,000 US dollars

Amvuttra - Europe

232,323,000 US dollars

GIVLAARI - Rest of World

12,454,000 US dollars

GIVLAARI - UNITED STATES

107,091,000 US dollars

GIVLAARI - Europe

44,613,000 US dollars

ONPATTRO - Rest of World

5,840,000 US dollars

ONPATTRO - UNITED STATES

20,029,000 US dollars

ONPATTRO - Europe

13,073,000 US dollars

OXLUMO - Rest of World

20,865,000 US dollars

OXLUMO - UNITED STATES

35,510,000 US dollars

OXLUMO - Europe

47,068,000 US dollars

Cost of collaborations and royalties

3,792,000 US dollars

Research and development

778,000,000 US dollars

Selling, general and administrative

670,473,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.